click here to continue to article cliquez ici pour lire l'article weiter zum Artikel clicca qui per visualizzare l'articolo weiter zum Artikel ir a la noticia klik hier om door te gaan naar het artikel Yazya devam etmek iin tklayn Tovbb a cikkre
Go here to read the rest:
China completes successful docking mission at space station.
See the original post here:
The Red Sox have traded veteran third baseman Kevin Youkilis to the White Sox, Chicago's South Siders have confirmed.
The three-time American League All-Star third baseman was acquired in exchange for infielder Brent Lillibridge and right-handed pitcher Zach Stewart. The White Sox also received a cash payment in the trade.
According to TV station WBZ, Youkilis tipped his helmet, blew a kiss to the crowd before leaving Sunday's game.
Youkilis was a member of Red Sox World Championship teams in 2004 and 2007, the White Sox pointed out in a statement. He ranks among the clubs all-time postseason leaders and is hitting .225 with four home runs and 13 RBI in 41 games this season.
He was on the disabled list in May with lower back tightness.
Original post:
Mon, Jun 25, 2012
In an effort to accelerate technology transfer from NASA into the hands of American businesses, industry and the public, the agency's new Technology Transfer Portal is open for business.
NASA's Technology Transfer Portal provides an Internet-based one-stop front door to the agency's unique intellectual property assets available for technology transfer and infusion into America's new technology and innovation-driven economy. NASA's Technology Transfer Program allows research and development to transfer back into the U.S. economy via licenses, patents and intellectual property agreements that often result in new innovations, products and businesses. The use of NASA technology by American businesses spurs job growth and helps maintain U.S. economic competitiveness while improving our everyday lives.
"One of NASA's highest priority goals is to streamline its technology transfer procedures, support additional government-industry collaboration and encourage the commercialization of novel technologies flowing from our federal laboratories," said NASA Administrator Charles Bolden at NASA Headquarters in Washington. "One way NASA can streamline and increase the rate of aerospace technology transfer is through tools like NASA's Technology Transfer Portal."
NASA designs technologies to solve difficult problems in space and on Earth. Some examples include NASA-developed devices designed to operate remotely and with limited servicing in the harsh environment of space, and strong and lightweight materials that can withstand the extreme temperatures of supersonic flight or space travel. NASA has designed lifesaving techniques, protocols, and tools for use when orbiting the Earth and the nearest doctor is more than 200 miles below. Closed environment recycling systems, as well as energy generation and storage methods also have useful applications here on Earth.
NASA's new tech portal simplifies and speeds access to the agency's intellectual property portfolio, much of which is available for licensing. The site features a searchable, categorized database of NASA's patents, a module for reaching out to a NASA technology transfer specialist and articles about past successful commercialization of NASA technology. Historical and real-time data for NASA's technology transfer program also are available.
"A priority of NASA is to get federally-funded new technologies into the commercial marketplace," said NASA Chief Technologist Mason Peck. "We're hopeful that entrepreneurs, businesses of all sizes and anyone looking for innovative solutions to technology problems will explore NASA's Technology Transfer Portal to find opportunities to transfer NASA technologies into innovative solutions for the nation."
More here:
Open For Business: NASA Launches New Technology Transfer Portal
NASAs Mars Science Laboratory is on its way. In a little more than a month, the 1-ton rover, which launched in November, will descend to the Martian surface.
The nuclear-powered robot is designed to make spectacular new discoveries about the Red Planet. It will drill and analyze the Martian soil to search for signs of water, past or present, and determine whether or not the planet was ever able to support life.
MSL dwarfs its immediate predecessors, the rovers Spirit and Opportunity and could almost crush the first Martian rover, Sojourner, beneath one wheel. Bringing a robot this large down safely necessitates a never-before-attempted landing system, though the increased size has let scientists pack 10 state-of-the-art instruments aboard and should allow the robot to rove farther than any before.
Every time we land a new rover on Mars, our ability to understand the surface increases tremendously, said geologist John Grotzinger of Caltech who is the project scientist for the mission.
While scientists dont know exactly what new findings await the rover, they have good ideas of what they want to look for. The first few weeks of MSLs life on Mars are already planned out in detail and after the mission starts in earnest, researchers have a number of targets they are eager to explore.
Here, Wired takes a look at MSLs game plan after it gets its wheels on the ground on Aug. 5, and the early discoveries scientists are hoping to make.
Above:
MSLs sky crane represents a brand new way to get a rover down to the surface of Mars. When the lander approaches the ground, it will fire rockets and hover 25 feet over the surface and then gently lower the robot down on wires. This landing system represents the limits of current technology, making MSL the largest mass to ever touch down on the Red Planet.
The new method doesnt ruffle the science team too much.
Were actually really excited about the fact that weve got this guided entry capability, said Grotzinger, adding that it allowed researchers to pinpoint their landing site with greater precision than ever. People get nervous about sky crane, but its really a better landing system from a safety point of view.
Here is the original post:
TheInstitute for Research in Molecular Medicine (INFORMM) began as a multi-disciplinary cluster-based research programme spearheaded by 11 principal researchers from the Schools of Medical Sciences, Dental Sciences, Health Sciences and MITD (Medical Innovation and Technology Development Unit) located at the USM Health Campus in Kelantan. In 2003, after a rigorous audit exercise INFORMM was established following a formalised recognition accorded by the university and the Ministry of Higher Education. This was also the first time in the history of USM that an institute was formed bottom-upthrough efforts of a group of researchers in a cluster.
From the initial members of the loose research cluster, INFORMM now boasts 20 full-time PhD qualified lecturers. The multidisciplinary character of the institution has been maintained and is reflected in the staff development plan of its younger members, who have been trained in the latest techniques in biotechnology and molecular biology. This has enabled the institution to grow from strength to strength, culminating in it being recognised as a Higher Education Centre of Excellence (HiCoE) by the Ministry of Higher Education in 2008.
Physically, INFORMM straddles East and West Malaysia, having a purpose-built building in both the Kelantan and Penang campuses of USM. Within these two facilities are housed roughly 90 postgraduate students doing full-time research in molecular medicine. Research at INFORMM is cluster-based, concentrated on translational and fundamental research. Each research cluster comprises a group of scientists with differing expertise but with a common research focus area.
Contributions from these individual scientists towards a common goal help to focus and accelerate research findings and optimise research output. In practice, research in INFORMM adopts the R-D-C-E (Research - Development - Commercialisation - Entrepreneurship) concept, where research development and innovation are performed under one roof to bring the innovation to the marketplace in a timely manner. These approaches have led INFORMM to achieve success in its research output and subsequently transform these into commercialised products or licensed technology. The R-D-C-E approach adopted by INFORMM for its research and innovation activities is also now subscribed by many research organisations in Malaysia.
Grooming Postgraduate Students: In a short space of less than 10 years, INFORMM has successfully obtained research grants of more than RM26 million and the research output, measured by the number of publications and cumulative impact factors, have been steadily increasing. The institute has also seen success in the commercialisation and licensing of its innovations. As with any other research institution, while the fundamental knowledge, ideas and inspiration comes from the academia, the output and successes will not be possible without industrious postgraduate students.
INFORMM encourages and recruits bright and promising students from all over the world to join the institute as postgraduate students in order to catapult INFORMM to a world-class level. Currently the postgraduate enrolment is 90 students with 60 per cent pursuing their masters studies, and 40 per cent, their doctorates. The number of students is expected to exceed 100 this year.
As the student numbers approach saturation, the emphasis will be on increasing the percentage of high quality doctorate students. This is seen as a natural progression as the institute matures, and the quality of its research will be its ultimate sustaining factor.
Whilst it is assumed that postgraduate students need to spend hours upon hours acquiring specialised skills and running experiments, those at INFORMM also receive an all-round education, in addition to the technical skills that are needed for their research. During their stint in the institute, they undergo soft skill development, communication skills development and project management skills.
Weekly journal club presentations, annual students colloquiums, regular technology enhancement lectures and invited speaker lectures are practised. This year, an element of entrepreneurial training and exposure is being introduced as a soft start to academic entrepreneurship. This is seen as very relevant, to the R-D-C-E concept, which has shown good results in a relatively short time. The postgraduate students also work in an ISO 9001 regulated environment and are trained to adhere to the standard operating procedures and management practices of INFORMM. INFORMM is constantly in dialogue using regular student-director meetings to ensure they receive the best training possible as scientists as well as future engineers in the nations development.
See original here:
24-06-2012 12:49 Two strikes! Hurry! Sub zeh back-up! Re-uploading this upon request :3 Not too much to say about this amv ... I remember when I first started working on it how I told my friend that I was super psyched about it and thought it to be one of my greatest creations x'D Soon after I detested it and realized all the errors within it ee' What can I say ... ? The harshest critic is always yourself lol vv' But don't mind me~
See more here:
Howies founders David and Clare Hieatt have launched a new venture, Hiut Denim Co, to revive Cardigan's denim industry
BY Georgia Dehn | 23 March 2012
In May last year the entrepreneur David Hieatt appeared on the front page of his local newspaper in Cardigan, west Wales, appealing for skilled machinists with specialist knowledge of making jeans to work in a new denim factory in the area. Hieatt, who founded the action sports clothing company Howies in 1995 with his wife, Clare (they sold it to Timberland in 2006), was in the process of launching a new venture, Hiut Denim Co. In response to the newspaper article, he was inundated with applications from locals, many of whom said the same thing: 'I want to make jeans again.'
Almost a decade ago, 400 people in Cardigan, a tenth of the town's population, with hundreds of years' experience making jeans between them, were made redundant when the Dewhirst Group shut the doors to its clothing factory and moved production to Morocco. Dewhirst was Cardigan's biggest employer and the factory had been producing 35,000 pairs of jeans each week for the likes of Marks & Spencer and Gap. Hieatt wanted to give locals the opportunity to put their skills to good use again. He rented an industrial unit, in which the company has now been installed for three months. The walls are clad in pitch pine from an old flour mill and Hieatt bought 24 sewing machines from an old Wrangler factory in Poland. After interviewing 'lots of eager women' who used to work at Dewhirst, he hired three and named them his 'Grand Masters'. Hieatt also took on a cutter who had worked at Dewhirst for 38 years, and a mechanic to fix the machines when they went wrong.
Hiut Denim Co may be a tiny start-up, but 'Levi's started small too,' Hieatt says. 'Our aim for the first year is to sell 2,500 pairs of jeans.' Mostly they will be sold online, but also in about 20 specialist denim shops around the world. Hieatt wants to build up the company so that he can offer everyone who worked at Dewhirst their old job back: 'We have to get everyone in this town making jeans again.' At a time when provenance matters greatly to consumers, manufacturing his product in Britain gives Hiut Denim Co a head start in the market, but Hieatt says he 'can't count on craftsmanship alone'. What he needs to do, he says, is to 'change the jeans industry through ideas.'
Hieatt is an ideas man and always has been. Before establishing Howies, he worked as a copywriter at the Saatchi & Saatchi advertising agency in London. 'I was working with bright and driven people,' he says. After Howies, he and Clare founded the Do Lectures - a five-day event (now in its fifth year) at an upmarket campsite in west Wales to which they invite inspiring individuals from around the world, including authors and entrepreneurs, to 'come and tell us what they do'. It is essentially a festival of good ideas, a 'Glastonbury of the mind'.
Hieatt has called on some of his more technologically minded friends to help him with his big idea for Hiut Denim Co. 'We are building an app called History Tag,' he says, 'and our jeans will be the first in the world that will have their whole history recorded.' To start with, Hiut Denim Co will sell two styles (men's only): one in selvage denim (sourced in Japan), the unwashed, raw, real indigo kind; and one in organic denim (sourced in Turkey). Each pair produced will have a code sewn into them and at each stage of production Hieatt's Grand Masters will photograph the jeans for the History Tag app - 'so when you buy a pair of jeans you will not only get a receipt, you will get pictures of your jeans being born. As you go through your life with your jeans you will be able to upload all your pictures of where you go and what you did wearing them,' he says. 'Then when those jeans are handed down or end up in a second-hand store, their history will go along with them too. This idea will become a badge of honour for companies who make products that last, and the longer you make something last the more stories it has to tell.'
hiutdenim.co.uk
Read the original post:
Huit Denim Co: The jeans with the app that tells their history
TAIPEI, June 25, 2012 /PRNewswire-Asia/ -- TaiGen Biotechnology Company, Limited ("TaiGen") and Zhejiang Medicine Company, Limited ("ZMC") today announced that they have signed an exclusive agreement to manufacture and commercialize nemonoxacin, a novel broad-spectrum antibiotic, in China (excluding Hong Kong, and Macau). Nemonoxacin is a novel broad-spectrum non-fluorinated quinolone antibiotic under development for respiratory infections. TaiGen will be responsible for completing the Phase 3 clinical trial for community acquired pneumonia ("CAP") in China. ZMC will be responsible for manufacturing, sales and marketing of nemonoxacin in China through its wholly-owned subsidiary, XinChang Pharmaceuticals. TaiGen will retain full development and commercialization rights outside the licensed territory including Taiwan, the United States, European Union, and Japan. Under the terms of the agreement, TaiGen will receive an upfront payment of US$ 8 million from ZMC and will receive additional milestones as well as royalties on product sales. The term of the agreement is 20 years.
Nemonoxacin has demonstrated efficacy and safety in CAP and diabetic foot infection in multinational and multi-center clinical trials conducted by TaiGen. In particular, nemonoxacin has excellent activity against drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and quinolone-resistant MRSA. Nemonoxacin is taken once-a-day and available in both oral and intravenous formulations. Currently, TaiGen is completing a Phase 3 CAP trial with more than 500 patients from Taiwan and mainland China and expects to file new drug applications in Taiwan and mainland China simultaneously in early 2013.
China is one of the major antibiotic markets in the world. According to IMS, the sales of antibiotics in 2011 were approximately US$ 11 billion (RMB 68 billion) and account for almost 20% of the total pharmaceuticals sales. Rate of antibiotic resistant infections in China is among the highest in the world.
Mr. Li Chun Bo, Chairman of the ZMC, commented, "We are impressed with nemonoxacin's broad spectrum activity towards drug-resistant bacteria, in particular, MRSA, and excellent safety profile. We are excited to establish this partnership with TaiGen because of its reputation as a premier research-based biotech company in Asia. This partnership will break new ground for cross-strait collaboration in the pharmaceutical industry. Nemonoxacin will be a major addition to ZMC's antibiotic product line and significant profit driver".
Dr. Ming-Chu Hsu, President and Chief Executive Officer of TaiGen, said, "China is the world's fastest growing pharmaceutical market. It is poised to overtake Japan as the second largest pharmaceutical market. We are extremely please to establish our nemonoxacin partnership with ZMC, a first-class pharmaceutical company and major player in the Chinese antibiotics market. With nemonoxacin, TaiGen and ZMC together will bring new medicine to treat unmet medical needs in China. This partnership will not only set a new record for pharmaceutical licensing involving a Taiwanese and a mainland Chinese company but hopefully will also become a model of the future collaborations," Dr. Hsu also added, "With the conclusion of the partnership in China, we will actively pursue nemonoxacin licensing discussions in other territories such as European Union."
About Zhejiang Medicine
Zhejiang Medicine Company, Limited is a leading pharmaceutical company in China specializing in sales and distribution of pharmaceuticals and manufacturing of active pharmaceutical ingredients (vitamins and antibiotics). Its sales revenue in 2011 is US $740 million (RMB 4.8 billion). ZMC is a leader in the Chinese antibiotic market with levofloxacin, vancomycin, and teicoplanin in the product line. ZMC's Lai Li Xin, a branded levofloxacin, is one of the top selling antibiotics in China with 2011 sales exceeding US $110 million (RMB 735 million). In addition to pharmaceuticals sales, ZMC is also known for its manufacturing quality. Its vancomycin active pharmaceutical ingredient has obtained GMP qualification from US Food and Drug Administration (FDA) and exported to western countries. ZMC is publicly listed in the Shanghai Stock Exchange (600216) and has a market capitalization of RMB 11 billion.
About TaiGen Biotechnology
TaiGen Biotechnology is a leading research-based and product-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, mainland China. TaiGen has full discovery research capacity in Taiwan and clinical development in mainland China/Taiwan/US. In addition to nemonoxacin, TaiGen has two other in-house discovered new chemical entities in clinical development under IND with US FDA: TG-0054, a chemokine receptor antagonist for stem cell transplantation and chemosensitization, in Phase 2 and TG-2349, a HCV protease inhibitor for treatment of chronic hepatitis infection, in Phase 1. Both TG-0054 and TG-2349 are currently in clinical development in the US.
Disclaimer
Link:
NEWARK, N.J. (AP) -- The Atlanta Dream didn't panic when the New York Liberty made a run late in the first half to take a lead at the break. They just regrouped and took control of the game in the third quarter.
Angel McCoughtry scored 23 points and Sancho Lyttle added 19 to lead the Dream to a 74-64 victory Sunday.
"We just can't let outside things get in our head," McCoughtry said when asked what the team discussed after giving up a 10-point lead and trailing by two at halftime. "We were a little frustrated with some calls, a little frustrated with the way we were playing, and how they were making their run. It's called adversity, it happens. It's the game."
McCoughtry was 7-for-20 from the field and 8-for-10 on free throws in her return after missing two games due to a knee injury, helping the Dream (5-7) snap a two-game skid.
Lyttle scored nine points, Armintie Price had five and McCoughtry added five points and four rebounds as Atlanta outscored New York 25-10 in the third quarter to take a 13-point lead.
"It's not because of me. It's a team effort and everybody coming together, regrouping after a loss," McCoughtry said. "(Lyttle) hit a couple of 3s ... she has the highest 3-point percentage shooting on the team and she's a post player. Armintie got some great rebounds, got fouled. Lindsey (Harding) is coming back slowly."
Leilani Mitchell scored 16 points, Kara Braxton had 14 points and 13 rebounds, and Cappie Pondexter and DeMya Walker added 12 points each as the Liberty (4-9) lost for the fourth time in five games. New York's lone win during that stretch came at Atlanta last Tuesday in a game McCoughtry missed.
Pondexter fouled out of the game late in the fourth quarter as the Liberty were trying to make a surge. She finished 4 for 17 from the field with seven turnovers.
"We couldn't make shots tonight," Pondexter said. "They did a great job of adjusting. We were the last game they played and obviously they made a lot of adjustments. ... We just got to learn to be consistent. It's kind of up and down, it's kind of hard for us to get it together."
The Liberty had 26 turnovers, which led to 31 points for the Dream. Atlanta had 16 turnovers, leading to nine points for New York.
See the article here:
25 June 2012 Last updated at 04:50 ET
The Scottish government has announced that it will spend 120m to bring superfast broadband to communities in the Highlands and Islands.
Public agency Highlands and Islands Enterprise (HIE) is in discussions with BT about delivering the upgrade.
The programme of works will include laying underground and subsea cables.
Secretary for Infrastructure and Capital Investment, Alex Neil, said improved internet speeds would benefit business and education.
He announced the Scottish government-funded investment in superfast broadband at a meeting of the Convention of Highlands and Islands, which involves the government and local authorities.
The spending forms part of the Scottish government's Scotland's Digital Future: Infrastructure Action Plan.
Mr Neil said: "Scotland's ambition to deliver world-class digital connectivity by 2020 has received a boost today, with the announcement of 120m for the Highlands and Islands.
"Everybody in the Highlands and Islands recognises the importance of access to superfast broadband, not just for the future of our local economies but indeed for the future of our children, for our education, our health and every aspect of life in the modern world."
View original post here:
Superfast broadband is to be brought to rural communities in the Highlands and Islands.
Read more from the original source:
The Pirates of the Caribbean films were smash-hit successes and undoubtedly heightened Johnny Depp's heartthrob status. But they also shed light on the bountiful beauty of the islands so head for the high seas and have your own adventure in what was once a pirate paradise.
With its pure white beaches, calm waters and year-round sunshine the Caribbean is understandably a popular holiday destination. This heavenly corner of the American continent beckons the lure of lazy days on the beach soaking up the sun, opportunities for diving and enjoying well-earned rest in some of the world's best hotels.
CLICK ON PHOTO FOR FULL GALLERY
Captain Jack Sparrow (Johnny Depp), the charismatic roguepirate in the film series stole our hearts with his rum-swigging antics. Many of his swashbuckling scenes were shot against the stunning backdrop of the Caribbean. When we could divert our eyes from Captain Sparrow or, indeed, the more reserved Will Turner (Orlando Bloom), we were completely charmed by the scenic surroundings. The films captured the spirit of the idyllic islands: tiny coastal towns where past and present fuse together, and where the ancient maritime spirit still runs deep.
Begin your Caribbean break in the Bahamas, a country consisting of more than 3,000 islands, cays and islets. Its capital, Nassau, spans most of New Providence Island and has a colourful history. Once a pirate hotspot, it was later home to free slaves and rum bootleggers. Although stories of its privateer past are still recounted, nowadays the Bahamas are better known for their spectacular beauty.
Follow in the casts footsteps and head south to Grand Bahama Island, then to White Cay, where the second film Dead Mans Chest was shot in 2006. A short 35 minute hop by plane from Miami, White Cay has some of the worlds clearest waters and is abundant with seemingly endless stretches of white beach and fabulous coral reefs.
Dominica, the most northern of the Windward Islands, claims to have one of the world's largest undiscovered hoards of treasure. Apart fromits mysterious stash of jewels, the island also boasts some of the most pristine beaches in the Caribbean. Home to colourful coral reefs inhabited by sea tortoises, it is rated highly for its diving spots. Captain Jack Sparrows beloved Black Pearl ship was anchored in the islands Prince Rupert Bay.
The rest is here:
LEXINGTON, Mass. & NUREMBERG, Germany--(BUSINESS WIRE)--
RainDance Technologies, Inc., the Digital Biology Company, today announced the introduction of its new RainDrop Digital PCR System to the European genetics research market. Attendees of the annual European Society of Human Genetics (ESHG) meeting in Nuremberg, Germany have the opportunity to see demonstrations of the system, which establishes new performance standards in sensitivity, multiplexing and absolute quantitation in PCR analysis.
Capable of generating more than a billion reactions in a single day, the RainDrop System transforms the performance of molecular assays by enabling digital answers across a number of important applications including low-frequency tumor allele detection, gene expression, copy number variation, and SNP measurement. Since each droplet encapsulates a single molecule, researchers can quickly determine the absolute number of specific target DNA and compare that to the background wild-type DNA. The RainDrop System also shifts the current digital PCR (dPCR) paradigm from a single-color-per-marker approach to a two color with varying probe intensity method that is capable of multiplexing up to 10 markers.
With the introduction of the RainDrop System at ESHG, we have officially ushered in the next generation of PCR for European researchers, said Mark Dronsfield, Ph.D., European Sales Director at RainDance. Europe is home to a number of the worlds leading research organizations and we are already actively engaged with many of them who are interested in bringing the power of a billion reactions with digital answers to their projects.
In a recent Lab on a Chip paper, scientists from Universit de Strasbourg and Universit Paris Descartes, used the RainDance dPCR technology to detect a single mutated copy of KRAS in a background of 200,000 wild-type copies. By processing reactions in millions of picoliter droplets, the platform improved sensitivity by two orders of magnitude compared to existing technologies.
RainDance will be showcasing the new RainDrop System at ESHG in booth #418. For more information, please visit: http://www.RainDanceTech.com/ESHG.
About RainDance Technologies
RainDance Technologies, the Digital Biology Company, is pioneering the use of high-throughput picodroplet-based analysis in human health and life science research. The company's core RainStorm technology generates millions of discrete droplets that can encapsulate a single molecule, cell or reaction and be digitally analyzed and sorted one at a time. The power, precision and simplicity of picodroplets enable researchers to answer complex questions with unprecedented sensitivity and quantitation. The complete RainDance solution includes automated instrumentation, customizable bioinformatics and high-value consumables and reagents for applications including targeted next-generation DNA sequencing, methylation, digital PCR. Based in Lexington, Massachusetts, the company supports scientists around the world through its international sales and support operations and a global network of distributors and service providers. For more information, please visitwww.RainDanceTech.com.
The RainDance products are for research use only. Not for use in diagnostic procedures.
RainDance Technologies, the RainDance Technologies logo, RainDrop, RainStorm, and Digital Biology are trademarks of RainDance Technologies, Inc. All other brands may be trademarks of their respective holders.
Read more:
RainDance Technologies Unveils Digital PCR Platform to European Market
ZURICH, Switzerland--(BUSINESS WIRE)--
Myriad Genetics GmbH announced today that a presentation entitled Current Variant of Uncertain Significance Rates in BRCA 1/2 and Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) Testing, was presented today at the European Human Genetics Conference in Nurnberg, Germany. The study highlights Myriads best-in-class variant classification process and variant of uncertain significance rate.
Researchers analyzed the variant of uncertain significance rate for the BRACAnalysis test (BRCA 1 and BRCA 2 genes) test as well as the COLARIS test (MLH1, MSH2, MSH6, PMS2 and EPCAM genes). From 2002 to 2012, Myriads overall uncertain variant rate decreased due to significant investments made in the development and application of improved processes and statistical techniques and the implementation of a targeted program designed to gather data on family members. Across all ancestries, the BRCA 1 and BRCA 2 variant of uncertain significance rate declined from 12.8% to 2.9%. Further, the variant of uncertain significance rate for Lynch syndrome, a test analyzing the MLH1, MSH2, MSH6, and EPCAM genes, declined to 6.6% in 2012. The variant of uncertain significance for PMS2 gene test, also for Lynch Syndrome, was 4.0%.
This data underscores the importance of a world-class variant classification program as well as the high level of accuracy and sensitivity of Myriads genetic tests. Further, through the investment in research and development for its existing tests, the Company has deepened its understanding of variants and variant classification. Myriad continues to invest furthering this knowledge base in an effort to provide best-in-class testing to patients globally.
Current tests available in Europe have a very high variant of uncertain significance rate, often 25 to 30 percent, stated Gary King, Executive Vice President of International Operations at Myriad. We are pleased to bring Myriads technology and variant classification program to Europe, to enhance the quality of genetic testing available to patients and physicians.
About Myriad Genetics GmbH
Myriad Genetics GmbH is the international headquarters of Myriad Genetics, Inc., a global molecular diagnostic company. The Company is dedicated to making a difference in patients lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of nine molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a focus on improving an individual's decision making process for monitoring and treating disease. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.
Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Companys variant classification program; and the Companys strategic directives under the caption About Myriad Genetics. These forward-looking statements are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and companion diagnostic services may decline or will not continue to increase at historical rates; the risk that we may be unable to expand into new markets outside of the United States; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and companion diagnostic services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and companion diagnostic services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and companion diagnostic services and any future products are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with manufacturing our products or operating our laboratory testing facilities; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of healthcare payment systems; risks related to our ability to obtain new corporate collaborations and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we acquire; the development of competing tests and services; the risk that we or our licensors may be unable to protect the proprietary technologies underlying our tests; the risk of patent-infringement and invalidity claims or challenges of our patents; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading Risk Factors contained in Item 1A in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.
Continue reading here:
Myriad Presents Variant of Uncertain Significance Rates at European Human Genetics Conference 2012
23-06-2012 14:20 Delivering the Republicans' weekly address, Rep. Bill Cassidy, R-La., a doctor, argued the president's health care reform law - the fate of which will rest in the hands of the Supreme Court next week - "continues to hurt job creation and damage our economy."
Read the rest here:
Rep. Cassidy: SCOTUS must repeal Obama's health care law - Video
The U.S. Supreme Court could be on the verge of a ruling on the Affordable Care Act. A look at one couple's situation.
Tue, Mar 20, 3:12 p.m.
Washington lawmakers gear up for the introduction of Obamacare. Even as it faces its day in the Supreme Court.
Wed, Jan 11, 2 a.m.
A doctor tells legislators: Yes, the lack of insurance does cause deaths. The lawmakers got an early briefing on declining access to health care, which could worsen with further state budget cuts.
Amy Moreno-Sills loves sustainable farming. It's a passion. A core of her beliefs. The life work of her and her husband, Augustin.
And she faces possibly giving it up to get health insurance.
Augustin 29, and Amy, 37, are both managers for produce farms in Pierce County earning about $60,000 annually as a couple, an income that just dropped significantly with the recent brth of their second child, Hector. With a 4-year-old daughter Gabriela, Amy had to switch to a part-time administrative job at Terry's Berry Farm cutting more than $15,000 from the couple's annual income..
So far, the family has lived on the edge of having adequate health insurance. In fact, maybe beyond the edge.
Neither parent has health insurance. Particularly withday-care costs taking up a lot of their income, they can't afford it. "It's super-pricey. What are we gonna have to give up to have health insurance?" Amy said recently.
See more here:
The P.E.I. government is looking to unload two seniors homes and an old medical clinic that it no longer has any use for.
See the article here:
The U.S. Supreme Court will likely wait to the last moment to issue its decision on the Affordable Care Act, President Barack Obama’s health care initiative.
Here is the original post:
By Kevin BohnCNN Senior Producer
POSTED: 6:28 pm MDT June 24, 2012
UPDATED: 11:11 pm MDT June 24, 2012
Copyright CNN 2012
See more here: